A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Patients will be treated with irinotecan (150mg/m2) followed by oxaliplatin (85mg/m2)on day 1
and S-1(80mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned
treatment of maximum 12 cycles of chemotherapy. Response assessement will be performed every
2 cycles of chemotherapy.